{{Drugbox
| drug_name = 
| IUPAC_name        = 
| image             = 
| alt               = 
| caption           = 
<!--Clinical data -->
| tradename         = Elelyso / Uplyso (Latin America)
| Drugs.com         = {{drugs.com|monograph|elelyso}}
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = Rx-only
| routes_of_administration =  Intravenous infusion
<!--Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 18.9-28.7 minutes
| excretion         = 
<!--Identifiers -->
| CAS_number        = 37228-64-1
| ATCvet            = 
| ATC_prefix        = A16
| ATC_suffix        = AB11
| PubChem           = 
| DrugBank          = DB08876
| ChemSpiderID = none
| UNII = 0R4NLX88O4
| KEGG = D09675
| ChEMBL = 1964120
<!--Chemical data -->
| chemical_formula  =
| C=2580 | H=3918 | N=680 | O=727 | S=17
| molecular_weight  = 56637.9397 g/mol 
}}

'''Taliglucerase alfa''', commercially known as '''Elelyso''', is a [[biopharmaceutical]] drug developed by [[Protalix]] and [[Pfizer]].<ref>{{cite journal|pmc=2652073|title=A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I Investigation|year=2009|volume=4|issue=3|pmid=19277123|last1=Aviezer|first1=D|last2=Brill-Almon|first2=E|last3=Shaaltiel|first3=Y|last4=Hashmueli|first4=S|last5=Bartfeld|first5=D|last6=Mizrachi|first6=S|last7=Liberman|first7=Y|last8=Freeman|first8=A|last9=Zimran|first9=A|last10=Galun|first10=E|pages=e4792|doi=10.1371/journal.pone.0004792|journal=PLoS ONE|editor1-last=Ho|editor1-first=Paulo Lee|display-authors=8}}</ref><ref>{{cite web|url=http://clinicaltrials.gov/ct2/show/NCT00962260|title=Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease - Full Text View - ClinicalTrials.gov|publisher=}}</ref> The drug, a recombinant [[glucocerebrosidase]] used to treat [[Gaucher's disease]], was the first [[Pharming (genetics)|plant-made pharmaceutical]] to win approval by the [[U.S. Food and Drug Administration]].<ref>{{cite journal|url=http://science.sciencemag.org/content/320/5875/473|title=Is the Drought Over for Pharming?|first=Jocelyn|last=Kaiser|date=25 April 2008|publisher=|volume=320|issue=5875|pages=473–475|via=www.sciencemag.org|doi=10.1126/science.320.5875.473|pmid=18436771}}</ref><ref>Maxmen, Amy (2 may 2012) [http://blogs.nature.com/news/2012/05/first-plant-made-drug-on-the-market.html First plant-made drug on the market] Nature, Biology & Biotechnology, Industry, Retrieved 26 June 2012</ref> 
Each vial has 200 units of taliglucerase alfa.
==Approval history==
U.S. FDA New Drug Application (NDA) was granted approval in May 2012 for use in adults.<ref>[http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022458s000ltr.pdf NDA Approval]</ref><ref>[http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022458lbl.pdf Highlights of Prescribing Information]</ref>  U.S. FDA Supplemental New Drug Application (sNDA) for pediatric use was granted approved in August 2014.<ref>[http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022458Orig1s003,022458Orig1s006ltr.pdf Supplement Approval Fulfillment of Postmarketing Requirement]</ref>  In Israel, the Israeli Ministry of Health granted approval in September 2012.<ref>{{cite web | url=https://www.old.health.gov.il/units/pharmacy/trufot/PerutTrufa.asp?Reg_Number=148%2067%2033413%2000&safa=e | title=מאגר התרופות (Drug details for ELELYSO) |publisher=Ministry of Health Israel}}</ref> In Brazil, the Brazilian Health Surveillance Agency (ANVISA) granted approval in March 2013.  In Canada, Health Canada issued a Notice of Compliance in May 2014 for both adults and paediatric patients.<ref>{{cite web | url=http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_elelyso_140854-eng.php | title=Summary Basis of Decision (SBD): ELELYSO | publisher=Health Canada | date=2014-08-01 | archiveurl=https://web.archive.org/web/20140806003328/http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_elelyso_140854-eng.php | archivedate=2014-08-06}}</ref>

Taliglucerase alfa is made by the Israeli [[biotherapeutics]] company Protalix and sold by the American [[pharmaceutical company]] [[Pfizer]]

==See also==
* [[List of Israeli inventions and discoveries]]

==References==
{{Reflist}}

{{Other alimentary tract and metabolism products}}
{{Sugar hydrolases}}
{{Enzymes}}
{{Portal bar|Molecular and Cellular Biology|border=no}}

{{gastrointestinal-drug-stub}}

[[Category:EC 3.2.1]]
[[Category:Israeli inventions]]